Primary systemic chemotherapy of breast cancer: Indication and predictive factors

Hiromitsu Jinno, Michio Sakata, Tetsu Hayashida, Maiko Takahashi, Tomomi Sato, Hirohito Seki, Yuukou Kitagawa

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Primary systemic chemotherapy has become a standard of care for operable breast cancer patients who are candidates for adjuvant chemotherapy. Induction of pathological complete response (pCR) is one of the main goals of primary systemic chemotherapy because patients with pCR have shown a better prognosis. The definition of pCR has varied across clinical trials. It would be ideal for all researchers to use the same terminology in describing pathologic response. Identification of accurate predictive factors of pCR to primary systemic chemotherapy is urgent, because patients with a low chance of pCR and clinical response should be spared unnecessary toxicity. Early response to primary systemic chemotherapy might be correlated with a high probability of a pCR. Therefore, evaluation of early response is useful to avoid unnecessary toxicity without potential benefit from chemotherapy.

Original languageEnglish
Pages (from-to)74-79
Number of pages6
JournalBreast Cancer
Volume18
Issue number2
DOIs
Publication statusPublished - 2011 Apr

Fingerprint

Breast Neoplasms
Drug Therapy
Adjuvant Chemotherapy
Standard of Care
Terminology
Research Personnel
Clinical Trials

Keywords

  • Breast cancer
  • Predictive factor
  • Primary systemic chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Cite this

Primary systemic chemotherapy of breast cancer : Indication and predictive factors. / Jinno, Hiromitsu; Sakata, Michio; Hayashida, Tetsu; Takahashi, Maiko; Sato, Tomomi; Seki, Hirohito; Kitagawa, Yuukou.

In: Breast Cancer, Vol. 18, No. 2, 04.2011, p. 74-79.

Research output: Contribution to journalArticle

Jinno, Hiromitsu ; Sakata, Michio ; Hayashida, Tetsu ; Takahashi, Maiko ; Sato, Tomomi ; Seki, Hirohito ; Kitagawa, Yuukou. / Primary systemic chemotherapy of breast cancer : Indication and predictive factors. In: Breast Cancer. 2011 ; Vol. 18, No. 2. pp. 74-79.
@article{e1301e1742724aadb7394ff36e74cb54,
title = "Primary systemic chemotherapy of breast cancer: Indication and predictive factors",
abstract = "Primary systemic chemotherapy has become a standard of care for operable breast cancer patients who are candidates for adjuvant chemotherapy. Induction of pathological complete response (pCR) is one of the main goals of primary systemic chemotherapy because patients with pCR have shown a better prognosis. The definition of pCR has varied across clinical trials. It would be ideal for all researchers to use the same terminology in describing pathologic response. Identification of accurate predictive factors of pCR to primary systemic chemotherapy is urgent, because patients with a low chance of pCR and clinical response should be spared unnecessary toxicity. Early response to primary systemic chemotherapy might be correlated with a high probability of a pCR. Therefore, evaluation of early response is useful to avoid unnecessary toxicity without potential benefit from chemotherapy.",
keywords = "Breast cancer, Predictive factor, Primary systemic chemotherapy",
author = "Hiromitsu Jinno and Michio Sakata and Tetsu Hayashida and Maiko Takahashi and Tomomi Sato and Hirohito Seki and Yuukou Kitagawa",
year = "2011",
month = "4",
doi = "10.1007/s12282-010-0226-5",
language = "English",
volume = "18",
pages = "74--79",
journal = "Breast Cancer",
issn = "1340-6868",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Primary systemic chemotherapy of breast cancer

T2 - Indication and predictive factors

AU - Jinno, Hiromitsu

AU - Sakata, Michio

AU - Hayashida, Tetsu

AU - Takahashi, Maiko

AU - Sato, Tomomi

AU - Seki, Hirohito

AU - Kitagawa, Yuukou

PY - 2011/4

Y1 - 2011/4

N2 - Primary systemic chemotherapy has become a standard of care for operable breast cancer patients who are candidates for adjuvant chemotherapy. Induction of pathological complete response (pCR) is one of the main goals of primary systemic chemotherapy because patients with pCR have shown a better prognosis. The definition of pCR has varied across clinical trials. It would be ideal for all researchers to use the same terminology in describing pathologic response. Identification of accurate predictive factors of pCR to primary systemic chemotherapy is urgent, because patients with a low chance of pCR and clinical response should be spared unnecessary toxicity. Early response to primary systemic chemotherapy might be correlated with a high probability of a pCR. Therefore, evaluation of early response is useful to avoid unnecessary toxicity without potential benefit from chemotherapy.

AB - Primary systemic chemotherapy has become a standard of care for operable breast cancer patients who are candidates for adjuvant chemotherapy. Induction of pathological complete response (pCR) is one of the main goals of primary systemic chemotherapy because patients with pCR have shown a better prognosis. The definition of pCR has varied across clinical trials. It would be ideal for all researchers to use the same terminology in describing pathologic response. Identification of accurate predictive factors of pCR to primary systemic chemotherapy is urgent, because patients with a low chance of pCR and clinical response should be spared unnecessary toxicity. Early response to primary systemic chemotherapy might be correlated with a high probability of a pCR. Therefore, evaluation of early response is useful to avoid unnecessary toxicity without potential benefit from chemotherapy.

KW - Breast cancer

KW - Predictive factor

KW - Primary systemic chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=79956355254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956355254&partnerID=8YFLogxK

U2 - 10.1007/s12282-010-0226-5

DO - 10.1007/s12282-010-0226-5

M3 - Article

C2 - 20963524

AN - SCOPUS:79956355254

VL - 18

SP - 74

EP - 79

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 2

ER -